Biomerica, Inc. (BMRA)
NASDAQ: BMRA · Real-Time Price · USD
0.498
+0.057 (12.85%)
Feb 5, 2025, 12:45 PM EST - Market open
Biomerica Revenue
Biomerica had revenue of $1.64M in the quarter ending November 30, 2024, with 4.40% growth. This brings the company's revenue in the last twelve months to $5.58M, up 1.40% year-over-year. In the fiscal year ending May 31, 2024, Biomerica had annual revenue of $5.42M with 1.42% growth.
Revenue (ttm)
$5.58M
Revenue Growth
+1.40%
P/S Ratio
1.34
Revenue / Employee
$87,156
Employees
64
Market Cap
9.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2024 | 5.42M | 76.00K | 1.42% |
May 31, 2023 | 5.34M | -13.53M | -71.71% |
May 31, 2022 | 18.87M | 11.67M | 162.13% |
May 31, 2021 | 7.20M | 506.32K | 7.57% |
May 31, 2020 | 6.69M | 1.49M | 28.69% |
May 31, 2019 | Pro | Pro | Pro |
May 31, 2018 | Pro | Pro | Pro |
May 31, 2017 | Pro | Pro | Pro |
May 31, 2016 | Pro | Pro | Pro |
May 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
BMRA News
- 20 days ago - Biomerica Stock Trades 200% Higher After Prostate Screening Test Receives Approval - Benzinga
- 20 days ago - United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer - GlobeNewsWire
- 21 days ago - Biomerica Reports Second Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 2 months ago - Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis - GlobeNewsWire
- 3 months ago - Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements - GlobeNewsWire
- 3 months ago - Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain - GlobeNewsWire
- 4 months ago - Biomerica Reports First Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 5 months ago - The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer - GlobeNewsWire